GleamWall
中文EN

NTRR NEUTRA CORP.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1512886 · Fiscal year ends 01/31

Financial factors as of 2023-10-31 (2024Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-82.7%
TTM net income YoY-2.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin46.2%
Operating margin-1,457.1%
Net margin-2,723.6%
FCF margin—
EBITDA margin-1,103.4%

Returns

ROE—
ROA-758.7%
ROIC (approx.)—
Asset turnover0.28x

Leverage & solvency

Liabilities / assets3,574.0%
Debt / equity—
Current ratio0.02x
Interest coverage-14.07x

Cash quality & payout

Operating cash flow / net income0.02x
Accruals ratio-743.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20232023-01-31FY20222022-01-31
Income statement
Revenue$67,996$92,014
Cost of revenue$32,690$60,853
Gross profit$35,306$31,161
SG&A expense$227,974$508,482
Operating income-$297,675-$583,582
Interest expense$62,063$60,606
Pretax income-$557,894-$632,926
Income tax$3,523—
Net income-$561,417-$632,926
EBITDA-$218,769-$505,797
EPS (diluted)——
Balance sheet
Cash & equivalents$1,969$1,056
Inventory$23,846—
Current assets$25,815$2,666
PP&E, net$49,360$128,266
Total assets$75,175$130,932
Current liabilities$759,639$1.15M
Total liabilities$813,795$1.15M
Shareholders' equity-$773,820-$1.27M
Shares outstanding2.74B1.78B
Cash flow statement
Operating cash flow-$153,243-$405,615
Capital expenditure—$40,227
Free cash flow—-$445,842
Investing cash flow—-$40,227
Financing cash flow$154,156$423,590
Depreciation & amortization$78,906$77,785

Free plan shows the latest 2 periods; Pro shows all 12 🔒

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.